Reaction
Demyelinating Polyneuropathy reporting signals
As of the last recalculation, Demyelinating Polyneuropathy appears in 1,016 FAERS reports alongside 22 co-occurring drug terms. The strongest observed disproportionality signal is BUSULFAN (PRR 44.4).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Busulfan | 33 | 44.4 | 44.5 |
| Encorafenib | 11 | 23.0 | 23.0 |
| Brentuximab Vedotin | 11 | 22.2 | 22.2 |
| Bleomycin Sulfate | 10 | 20.0 | 20.0 |
| Felodipine Extended-Release Tablets | 10 | 18.2 | 18.2 |
| Felodipine | 10 | 18.2 | 18.2 |
| Dabrafenib | 18 | 17.8 | 17.8 |
| Atovaquone | 6 | 15.4 | 15.4 |
| Fludarabine Phosphate | 28 | 15.0 | 15.0 |
| Bendamustine Hydrochloride | 8 | 13.8 | 13.8 |
| Ipilimumab | 28 | 13.6 | 13.6 |
| Posaconazole Delayed-Release | 7 | 13.1 | 13.1 |
| Trametinib | 15 | 12.9 | 12.9 |
| Amikacin | 10 | 12.1 | 12.1 |
| Bendamustine Hcl | 8 | 10.6 | 10.6 |
| Panitumumab | 8 | 10.5 | 10.5 |
| Ifosfamide | 10 | 9.6 | 9.6 |
| Bortezomib | 40 | 9.5 | 9.5 |
| Nivolumab | 36 | 7.9 | 7.9 |
| Ixekizumab | 13 | 7.3 | 7.3 |
| Durvalumab | 6 | 6.1 | 6.1 |
| Dasatinib | 10 | 5.6 | 5.6 |